Loading...

We've got a brand new version of Simply Wall St! Try it out

Biosenta

CNSX:ZRO
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZRO
CNSX
CA$984K
Market Cap
  1. Home
  2. CA
  3. Household
Company description

Biosenta Inc. develops and deploys a range of anti-microbial products and remediation solutions for commercial and consumer applications. The last earnings update was 247 days ago. More info.


Add to Portfolio Compare Print
ZRO Share Price and Events
7 Day Returns
0%
CNSX:ZRO
-0.9%
North America Household Products
-0.1%
CA Market
1 Year Returns
100%
CNSX:ZRO
43.8%
North America Household Products
3%
CA Market
ZRO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biosenta (ZRO) 0% 0% - 100% -6.7% -
North America Household Products -0.9% 0.8% 11.4% 43.8% 30.6% 34.8%
CA Market -0.1% 2.9% 6.6% 3% 15.5% 5.9%
1 Year Return vs Industry and Market
  • ZRO outperformed the Household Products industry which returned 43.8% over the past year.
  • ZRO outperformed the Market in Canada which returned 3% over the past year.
Price Volatility
ZRO
Industry
5yr Volatility vs Market
Related Companies

ZRO Value

 Is Biosenta undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biosenta. This is due to cash flow or dividend data being unavailable. The share price is CA$0.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biosenta's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biosenta's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ZRO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in CAD CA$-0.04
CNSX:ZRO Share Price ** CNSX (2019-02-04) in CAD CA$0.07
North America Household Products Industry PE Ratio Median Figure of 8 Publicly-Listed Household Products Companies 24.66x
Canada Market PE Ratio Median Figure of 552 Publicly-Listed Companies 15.12x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biosenta.

CNSX:ZRO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ZRO Share Price ÷ EPS (both in CAD)

= 0.07 ÷ -0.04

-1.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biosenta is loss making, we can't compare its value to the North America Household Products industry average.
  • Biosenta is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Biosenta's expected growth come at a high price?
Raw Data
CNSX:ZRO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Household Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Household Products Companies 4.62x
Canada Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.19x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biosenta, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biosenta's assets?
Raw Data
CNSX:ZRO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in CAD CA$0.05
CNSX:ZRO Share Price * CNSX (2019-02-04) in CAD CA$0.07
North America Household Products Industry PB Ratio Median Figure of 13 Publicly-Listed Household Products Companies 1.83x
Canada Market PB Ratio Median Figure of 2,387 Publicly-Listed Companies 1.48x
CNSX:ZRO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ZRO Share Price ÷ Book Value per Share (both in CAD)

= 0.07 ÷ 0.05

1.52x

* Primary Listing of Biosenta.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biosenta is good value based on assets compared to the North America Household Products industry average.
X
Value checks
We assess Biosenta's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Household Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Household Products industry average (and greater than 0)? (1 check)
  5. Biosenta has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ZRO Future Performance

 How is Biosenta expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosenta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.8%
Expected Household Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biosenta expected to grow at an attractive rate?
  • Unable to compare Biosenta's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biosenta's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Biosenta's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ZRO Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Household Products Industry Earnings Growth Rate Market Cap Weighted Average 5.8%
North America Household Products Industry Revenue Growth Rate Market Cap Weighted Average 3.3%
Canada Market Earnings Growth Rate Market Cap Weighted Average 17.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ZRO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ZRO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-06-30 0 0 -1
2018-03-31 0 0 0
2017-12-31 0 0 -1
2017-09-30 0 0 -1
2017-06-30 0 0 0
2017-03-31 0 0 3
2016-12-31 0 0 3
2016-09-30 0 -1 3
2016-06-30 0 -1 1
2016-03-31 0 -1 -2
2015-12-31 0 -1 -3
2015-09-30 0 -1 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biosenta is high growth as no earnings estimate data is available.
  • Unable to determine if Biosenta is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ZRO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biosenta Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ZRO Past Financials Data
Date (Data in CAD Millions) EPS *
2018-06-30 -0.04
2018-03-31 -0.03
2017-12-31 -0.08
2017-09-30 -0.08
2017-06-30 -0.01
2017-03-31 0.29
2016-12-31 0.32
2016-09-30 0.37
2016-06-30 0.14
2016-03-31 -0.44
2015-12-31 -0.52
2015-09-30 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biosenta will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ZRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Biosenta's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Biosenta's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biosenta's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biosenta has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ZRO Past Performance

  How has Biosenta performed over the past 5 years?

  • Biosenta's last earnings update was 247 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biosenta's growth in the last year to its industry (Household Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biosenta does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Biosenta's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biosenta's 1-year growth to the North America Household Products industry average as it is not currently profitable.
Earnings and Revenue History
Biosenta's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biosenta Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ZRO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.00 -0.54 0.27 0.00
2018-03-31 0.00 -0.44 0.30 0.01
2017-12-31 0.00 -1.01 0.31 0.02
2017-09-30 0.02 -1.03 0.33 0.02
2017-06-30 0.03 -0.11 0.35 0.03
2017-03-31 0.05 3.11 0.47 0.02
2016-12-31 0.06 2.93 0.64 0.03
2016-09-30 0.08 2.75 0.79 0.03
2016-06-30 0.10 1.48 1.28 0.01
2016-03-31 0.10 -2.44 1.40 0.02
2015-12-31 0.14 -2.86 1.61 0.09
2015-09-30 0.12 -3.53 2.00 0.25
2015-06-30 0.07 -3.87 1.76 0.44
2015-03-31 0.12 -3.99 2.21 0.34
2014-12-31 0.08 -4.90 3.06 0.49
2014-09-30 0.06 -4.45 2.85 0.40
2014-06-30 0.03 -3.87 3.22 0.25
2014-03-31 0.01 -3.60 2.94 0.34
2013-12-31 0.09 -2.42 2.12 0.15
2013-09-30 0.34 -2.28 2.16 0.12
2013-06-30 0.39 -2.25 2.03 0.34
2013-03-31 0.33 -2.21 1.95 0.33
2012-12-31 0.25 -2.23 1.86 0.29
2012-09-30 -2.32 1.85 0.24
2012-06-30 -2.53 2.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biosenta has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biosenta has efficiently used its assets last year compared to the North America Household Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biosenta improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biosenta's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Household Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biosenta has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ZRO Health

 How is Biosenta's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biosenta's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biosenta's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Biosenta's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Biosenta's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biosenta Company Filings, last reported 10 months ago.

CNSX:ZRO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 0.65 0.22 0.01
2018-03-31 0.71 0.16 0.01
2017-12-31 0.17 0.66 0.02
2017-09-30 0.24 0.61 0.00
2017-06-30 1.15 0.58 0.01
2017-03-31 1.11 0.67 0.02
2016-12-31 1.19 0.59 0.00
2016-09-30 1.26 0.54 0.01
2016-06-30 1.21 0.53 0.01
2016-03-31 -3.04 3.50 0.02
2015-12-31 -2.79 3.32 0.00
2015-09-30 -2.51 3.00 0.02
2015-06-30 -1.14 2.40 0.02
2015-03-31 -0.49 2.07 0.01
2014-12-31 0.13 1.82 0.20
2014-09-30 0.89 1.35 0.30
2014-06-30 1.41 1.22 0.46
2014-03-31 2.41 0.55 0.56
2013-12-31 2.03 0.00 0.01
2013-09-30 1.54 0.00 0.00
2013-06-30 2.36 0.00 0.01
2013-03-31 2.83 0.00 0.04
2012-12-31 3.10 0.00 0.02
2012-09-30 2.19 0.01 0.02
2012-06-30 5.22 0.01 0.20
  • Biosenta's level of debt (34.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 34.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biosenta has less than a year of cash runway based on current free cash flow.
  • Biosenta has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.8% each year.
X
Financial health checks
We assess Biosenta's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biosenta has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ZRO Dividends

 What is Biosenta's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biosenta dividends.
If you bought CA$2,000 of Biosenta shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biosenta's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biosenta's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ZRO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Household Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biosenta has not reported any payouts.
  • Unable to verify if Biosenta's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biosenta's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biosenta has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biosenta's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biosenta afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biosenta has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ZRO Management

 What is the CEO of Biosenta's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dene Rogers
COMPENSATION CA$109,354
AGE 57
TENURE AS CEO 4.6 years
CEO Bio

Mr. Dene L. Rogers has been the President and Chief Executive Officer of General Wireless Operations Inc., since May 9, 2016. Mr. Rogers serves as the Chief Executive Officer and President of Biosenta Inc. Mr. Rogers has 10 years of successful retail experience in the USA, Canada and Australia. He served as the Chief Executive Officer and President of Biosenta Inc., since October 2014 and also its Interim Chief Financial Officer since February 17, 2015. He served as the Managing Director of Target Division at Wesfarmers Limited since October 17, 2011 and its Managing Director of Discount Department Store Chain Target since November 2, 2011 and served as senior executive at North American retail giant Sears. He served as the Chief Executive Officer of Sears Canada Inc., from December 22, 2006 to June 23, 2011 and its President from May 9, 2006 to June 23, 2011. He served as an Executive Vice President of Restructuring and Business Improvement at Kmart Holding Corporation, a wholly subsidiary of Sears Holdings Corporation since October 4, 2005. Mr. Rogers also served as Executive Vice President of Restructuring and Business Improvement at Sears Holdings Corporation since October 4, 2005. He served as Acting President of Sears Canada Inc., from October 4, 2005 to December 22, 2006. He also served as Senior Vice President of Store Operations at Kmart Holding Corporation since June 24, 2004. He joined Kmart Holding Corp. in October 2003 as the Head of Store Operations. As Executive Vice President and General Manager of Kmart Corp, he helped lead it’s turnaround during the 2003-2006 period. Prior to joining Kmart Holding Corporation in 2003, Mr. Rogers served as the Senior Vice President of Planning, Development and New Products at Starwood Hotels & Resorts Worldwide Inc., from 2001 to 2003. He served as Chief Executive Officer of Target Australia, where a significant increase in earnings, before one-off business transformation expenses, was delivered. Prior to retail, he was a Management Consultant of Booz Allen Hamilton. He served as Senior Vice President of Business Development at General Electric Capital before joining Starwood Hotels & Resorts Worldwide Inc., from 1998 to 2001. He has been an Interim Chairman of Biosenta Inc., since February 17, 2015. He serves as a Director of Fort Worth retailer. He served as a Director of Sears Canada from October 2005 to June 23, 2011. Mr. Rogers is a graduate of Yale University.

CEO Compensation
  • Dene's compensation has been consistent with company performance over the past year.
  • Dene's remuneration is lower than average for companies of similar size in Canada.
Management Team

Dene Rogers

TITLE
Interim Chairman
COMPENSATION
CA$109K
AGE
57
TENURE
4.6 yrs

Louis Nagy

TITLE
Consultant
COMPENSATION
CA$25K
Board of Directors Tenure

Average tenure of the Biosenta board of directors in years:

4.3
Average Tenure
  • The tenure for the Biosenta board of directors is about average.
Board of Directors

Dene Rogers

TITLE
Interim Chairman
COMPENSATION
CA$109K
AGE
57
TENURE
4.3 yrs

Ed Korhonen

TITLE
Independent Director
COMPENSATION
CA$10K
AGE
83
TENURE
10.9 yrs

David Butler

TITLE
Independent Director
COMPENSATION
CA$10K
TENURE
7.6 yrs

Nick Iacono

TITLE
Independent Director
TENURE
2.5 yrs

Am Gill

TITLE
Independent Director
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Biosenta's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biosenta has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ZRO News

Simply Wall St News

What Investors Should Know About Biosenta Inc.'s (CNSX:ZRO) Financial Strength

Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … (CNSX:ZRO) with its market cap of CA$984k, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Could Biosenta Inc's (CNSX:ZRO) Investor Composition Influence The Stock Price?

The big shareholder groups in Biosenta Inc (CNSX:ZRO) have power over the company. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of CA$703k, Biosenta is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Should You Be Concerned About Biosenta Inc's (CNSX:ZRO) Shareholders?

I am going to take a deep dive into Biosenta Inc’s (CNSX:ZRO) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

ZRO Company Info

Description

Biosenta Inc. develops and deploys a range of anti-microbial products and remediation solutions for commercial and consumer applications. The company offers household disinfectants and cleaners to kill deadly mold, fungi, bacteria, and viruses on contact and prevent re-growth under the ZeroMold name in Canada. It also focuses on manufacture and distribution of Tri-filler, an anti-microbial filler to perform filling and bulking functions like calcium carbonate for industrial use. In addition, the company engages in the development of Purity, a hospital-grade disinfectant for faster anti-microbial action; and True, a disinfectant and cleaner, which kills a multitude of potentially deadly microbes. It serves retail, institutional, and industrial users. Biosenta Inc. is based in Toronto, Canada.

Details
Name: Biosenta Inc.
ZRO
Exchange: CNSX
Founded:
CA$984,386
14,062,663
Website: http://www.biosenta.com
Address: Biosenta Inc.
18 Wynford Drive,
Unit 704,
Toronto,
Ontario, M3C 3S2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ZRO Class A Shares Canadian National Stock Exchange CA CAD 23. Oct 2015
Number of employees
Current staff
Staff numbers
0
Biosenta employees.
Industry
Household Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/03 02:59
End of day share price update: 2019/02/04 00:00
Last earnings filing: 2018/08/29
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.